Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 May;52(5):1108–1112. doi: 10.1172/JCI107276

Responsiveness of Growth Hormone-Deficient Children to Human Growth Hormone EFFECT OF REPLACEMENT THERAPY FOR ONE YEAR

Daniel Rudman 1,2,3,4, Joseph H Patterson 1,2,3,4, Donna L Gibbas 1,2,3,4
PMCID: PMC302365  PMID: 4700485

Abstract

Previous studies have shown that growth hormone (GH)-deficient children are more responsive to exogenous human growth hormone (HGH) than non-GH-deficient children. In six GH-deficient children, velocity of linear growth was less than 2.5 cm/yr. By the metabolic balance study technique, anabolic responses (increments in elemental balances) were measured to a 7 day course of 0.0532 U HGH/kg body weight (BW)3/4 per day (dose B) and to 0.168 U/kg BW3/4 per day (dose C). They were then treated for 1 yr with HGH at a dose intermediate between B and C. Velocity of linear growth accelerated to 15-25 cm/yr for the first 4-7 mo, then declined to 0-8 cm/yr. At 12 mo, responsiveness to doses B and C was measured again; the responses were only 20-60% as great as before treatment. After 3 mo without HGH treatment, responsiveness to the anabolic effects of doses B and C returned to the magnitudes observed before treatment. A low titer of plasma antibodies to HGH was detected in two of the six children at the end of the year's treatment; these titers showed little change after 3 mo without HGH. Thus the hyperresponsiveness of GH-deficient subjects to exogenous HGH, compared to non-GH-deficient individuals, declines during long-term HGH treatment and is restored by 3 mo interruption of treatment. These changes in peripheral responsiveness may be related to the decline in velocity of linear growth which occurs after 4-7 mo of continuous treatment.

When HGH was withdrawn after 12 mo, all six patients exhibited negative balances of N, P, Na, and K and loss of BW. Ratios of elemental balances showed about half the weight loss to represent protoplasm, and about half extracellular fluid. These observations indicate a role of GH in the continuing regulation of nitrogen and mineral metabolism in addition to its function as a growth-promoting hormone.

Full text

PDF
1108

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ESCAMILLA R. F., HUTCHINGS J. J., DEAMER W. C., LI C. H., FORSHAM P. H. Long-term effects of human growth hormone (Li) in a pituitary dwarf. J Clin Endocrinol Metab. 1961 Jun;21:721–726. doi: 10.1210/jcem-21-6-721. [DOI] [PubMed] [Google Scholar]
  2. HENNEMAN P. H., FORBES A. P., MOLDAWER M., DEMPSEY E. F., CARROLL E. L. Effects of human growth hormone in man. J Clin Invest. 1960 Aug;39:1223–1238. doi: 10.1172/JCI104138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Illig R. Growth hormone antibodies in patients treated with different preparations of human growth hormone (HGH). J Clin Endocrinol Metab. 1970 Dec;31(6):679–688. doi: 10.1210/jcem-31-6-679. [DOI] [PubMed] [Google Scholar]
  4. PRADER A., ILLIG R., SZEKY J., WAGNER H. THE EFFECT OF HUMAN GROWTH HORMONE IN HYPOPITUITARY DWARFISM. Arch Dis Child. 1964 Dec;39:535–544. doi: 10.1136/adc.39.208.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. RABEN M. S. Growth hormone. 2. Clinical use of human growth hormone. N Engl J Med. 1962 Jan 11;266:82–concl. doi: 10.1056/NEJM196201112660207. [DOI] [PubMed] [Google Scholar]
  6. RABEN M. S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958 Aug;18(8):901–903. doi: 10.1210/jcem-18-8-901. [DOI] [PubMed] [Google Scholar]
  7. ROTH J., GLICK S. M., YALOW R. S., BERSON S. A. ANTIBODIES TO HUMAN GROWTH HORMONE (HGH) IN HUMAN SUBJECTS TREATED WITH HGH. J Clin Invest. 1964 Jun;43:1056–1065. doi: 10.1172/JCI104989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. RUSSELL J. A. Effects of growth hormone on protein and carbohydrate metabolism. Am J Clin Nutr. 1957 Jul-Aug;5(4):404–416. doi: 10.1093/ajcn/5.4.404. [DOI] [PubMed] [Google Scholar]
  9. Rudman D., Chyatte S. B., Patterson J. H., Gerron G. G., O'Beirne I., Barlow J., Ahmann P., Jordan A., Mosteller R. C. Observations on the responsiveness of human subjects to human growth hormone. Effects of endogenous growth hormone deficiency and myotinic dystrophy. J Clin Invest. 1971 Sep;50(9):1941–1949. doi: 10.1172/JCI106686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rudman D., Chyatte S. B., Patterson J. H., Gerron G. G., O'Beirne I., Barlow J., Jordan A., Shavin J. S. Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy. J Clin Invest. 1972 May;51(5):1118–1124. doi: 10.1172/JCI106904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rudman D., Friedes D., Patterson J. H., Gibbas D. L. Diurnal variation in the responsiveness of human subjects to human growth hormone. J Clin Invest. 1973 Apr;52(4):912–918. doi: 10.1172/JCI107256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. SOYKA L. F., ZISKIND A., CRAWFORD J. D. TREATMENT OF SHORT STATURE IN CHILDREN AND ADOLESCENTS WITH HUMAN PITUITARY GROWTH HORMONE (RABEN). N Engl J Med. 1964 Oct 8;271:754–764. doi: 10.1056/NEJM196410082711502. [DOI] [PubMed] [Google Scholar]
  13. Tanner J. M., Whitehouse R. H., Hughes P. C., Vince F. P. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner's syndrome, and other complaints. Arch Dis Child. 1971 Dec;46(250):745–782. doi: 10.1136/adc.46.250.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. WRIGHT J. C., BRASEL J. A., ACETO T., Jr, FINKELSTEIN J. W., KENNY F. M., SPAULDING J. S., BLIZZARD R. M. STUDIES WITH HUMAN GROWTH HORMONE (HGH). Am J Med. 1965 Apr;38:499–516. doi: 10.1016/0002-9343(65)90128-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES